Device Trial Radar · NCT06096428
Hemolysis During Pulsed-field and Radiofrequency Ablation
Last checked: Nov 20, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
60
Planned (sponsor's estimate)
Start
Nov 15, 2023
Primary completion
Mar 30, 2024
Study completion Mar 30, 2024
Sponsor
- Lead sponsor
- Charles University, Czech RepublicAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 23, 2023
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
Summary
As written by the sponsor on the registry.
Hemolysis during and after catheter ablation will be compared between catheter ablation performed using radiofrequency and pulsed-field energy. Consecutive patients indicated for catheter ablation for AF will be enrolled, catheter ablation will be done using standard catheters (Qdot, Biosense Webster for RF, and Farapulse, Boston-Scientific for PF). Blood samples will be drawn at the beginning of ablation (T1), at the end of ablation (T2), and one day after the procedure (T3). Hemolysis will be analyzed using flow cytometry, ELISA and standard biochemistry and compared between RF and PF patients, Primary hypothesis is that hemolysis level will be higher after PF ablation compared to RF ablation.
Conditions
- Atrial Fibrillation
- Hemolysis
- Pulsed-field Ablation
Interventions
Pulsed-field ablationDevice
Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.
Radiofrequency ablationDevice
Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Erythrocyte (red blood cells, RBC) microparticlesTime frame: One day after the procedure
- Cell free hemoglobinTime frame: One day after the procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady
Prague, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.